1. Home
  2. AMAL vs SGP Comparison

AMAL vs SGP Comparison

Compare AMAL & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amalgamated Financial Corp. (DE)

AMAL

Amalgamated Financial Corp. (DE)

HOLD

Current Price

$41.34

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

SGP

SpyGlass Pharma Inc. Common Stock

N/A

Current Price

$21.07

Market Cap

932.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMAL
SGP
Founded
1923
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Commercial Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
932.9M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
AMAL
SGP
Price
$41.34
$21.07
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$36.00
$45.00
AVG Volume (30 Days)
106.7K
51.9K
Earning Date
04-23-2026
05-15-2026
Dividend Yield
1.68%
N/A
EPS Growth
N/A
N/A
EPS
0.84
N/A
Revenue
N/A
N/A
Revenue This Year
$21.18
N/A
Revenue Next Year
$6.55
N/A
P/E Ratio
$49.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.13
$20.15
52 Week High
$44.01
$30.56

Technical Indicators

Market Signals
Indicator
AMAL
SGP
Relative Strength Index (RSI) 52.78 36.44
Support Level $36.50 N/A
Resistance Level $42.70 $26.29
Average True Range (ATR) 1.09 1.54
MACD -0.03 -0.28
Stochastic Oscillator 54.98 2.59

Price Performance

Historical Comparison
AMAL
SGP

About AMAL Amalgamated Financial Corp. (DE)

Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.

About SGP SpyGlass Pharma Inc. Common Stock

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Share on Social Networks: